Capital Fund Management Reduces Stake in Incyte Corporation

Biopharmaceutical company's shares sold by investment firm during third quarter

Mar. 12, 2026 at 8:24am

Got story updates? Submit your updates here. ›

Capital Fund Management S.A. has reduced its position in Incyte Corporation (NASDAQ:INCY) by 26.0% during the third quarter, according to a recent SEC filing. The investment firm now owns 241,902 shares of the biopharmaceutical company's stock, valued at $20,516,000 at the end of the quarter.

Why it matters

Incyte Corporation is a prominent biopharmaceutical company focused on developing novel therapies for cancer, autoimmune disorders, and rare diseases. Changes in institutional ownership can provide insights into investor sentiment and market dynamics surrounding the company's stock.

The details

According to the 13F filing, Capital Fund Management sold 84,812 shares of Incyte during the third quarter. The firm now holds a total of 241,902 shares, down from 326,714 shares held previously. Incyte's stock price has fluctuated in recent quarters, trading between a 52-week low of $53.56 and a high of $112.29.

  • Capital Fund Management filed its 13F report for the third quarter of 2026.

The players

Capital Fund Management S.A.

A global investment management firm that oversees a diversified portfolio of assets.

Incyte Corporation

A biopharmaceutical company focused on developing novel therapies for cancer, autoimmune disorders, and rare diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Capital Fund Management's stake in Incyte Corporation reflects broader market dynamics and investor sentiment surrounding the biopharmaceutical industry. As a prominent player in the sector, changes in Incyte's institutional ownership can provide valuable insights for investors and analysts tracking the company's performance and growth prospects.